Literature DB >> 30673891

PBPK Absorption Modeling: Establishing the In Vitro-In Vivo Link-Industry Perspective.

Cordula Stillhart1, Xavier Pepin2, Christophe Tistaert3, David Good4, An Van Den Bergh5, Neil Parrott6, Filippos Kesisoglou7.   

Abstract

The establishment of an in vitro-in vivo correlation (IVIVC) is considered the gold standard to establish in vivo relevance of a dissolution method and to utilize dissolution data in the context of regulatory bioequivalence questions, including the development of dissolution specifications. However, several recent publications, including industry surveys and reviews from regulatory agencies, have indicated a low success rate for IVIVCs, especially for immediate-release formulations. In recent years, the use of physiologically based pharmacokinetics (PBPK) and absorption modeling, as a tool to facilitate formulation development, has been attracting increased attention. This manuscript provides an industry perspective on the current challenges with establishing IVIVCs and the potential PBPK and absorption modeling offer to increase their impact. Case studies across both immediate-release and extended-release formulations from five pharmaceutical companies are utilized to demonstrate how physiologically based IVIVC (PB-IVIVC) may facilitate drug product understanding and to inform bioequivalence assessment and clinically relevant specifications. Finally, PB-IVIVC best practices and a strategy for model development and application are proposed.

Keywords:  IVIVC; oral absorption modeling; physiologically based absorption modeling; physiologically based biopharmaceutics modeling; physiologically based pharmacokinetics

Mesh:

Substances:

Year:  2019        PMID: 30673891     DOI: 10.1208/s12248-019-0292-3

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  7 in total

1.  Deconvolution Analysis by Non-linear Regression Using a Convolution-Based Model: Comparison of Nonparametric and Parametric Approaches.

Authors:  Roberto Gomeni; Françoise Bressolle-Gomeni
Journal:  AAPS J       Date:  2019-12-09       Impact factor: 4.009

2.  Towards best use and regulatory acceptance of generic physiologically based kinetic (PBK) models for in vitro-to-in vivo extrapolation (IVIVE) in chemical risk assessment.

Authors:  Abdulkarim Najjar; Ans Punt; John Wambaugh; Alicia Paini; Corie Ellison; Styliani Fragki; Enrica Bianchi; Fagen Zhang; Joost Westerhout; Dennis Mueller; Hequn Li; Quan Shi; Timothy W Gant; Phil Botham; Rémi Bars; Aldert Piersma; Ben van Ravenzwaay; Nynke I Kramer
Journal:  Arch Toxicol       Date:  2022-09-05       Impact factor: 6.168

3.  Establishment of Level a In Vitro-In Vivo Correlation (IVIVC) via Extended DoE-IVIVC Model: A Donepezil Case Study.

Authors:  Da Young Lee; Soyoung Shin; Tae Hwan Kim; Beom Soo Shin
Journal:  Pharmaceutics       Date:  2022-06-09       Impact factor: 6.525

4.  In Vitro-In Vivo Correlation of Tianeptine Sodium Sustained-Release Dual-Layer Tablets.

Authors:  Ye-Ji Lee; Joo-Eun Kim
Journal:  Molecules       Date:  2022-04-29       Impact factor: 4.927

5.  Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series.

Authors:  Mark McAllister; Talia Flanagan; Susan Cole; Andreas Abend; Evangelos Kotzagiorgis; Jobst Limberg; Heather Mead; Victor Mangas-Sanjuan; Paul A Dickinson; Andrea Moir; Xavier Pepin; Diansong Zhou; Christophe Tistaert; Aristides Dokoumetzidis; Om Anand; Maxime Le Merdy; David B Turner; Brendan T Griffin; Adam Darwich; Jennifer Dressman; Claire Mackie
Journal:  Pharmaceutics       Date:  2022-05-07       Impact factor: 6.525

Review 6.  Development of In Vitro Dissolution Testing Methods to Simulate Fed Conditions for Immediate Release Solid Oral Dosage Forms.

Authors:  Timothy R Lex; Jason D Rodriguez; Lei Zhang; Wenlei Jiang; Zongming Gao
Journal:  AAPS J       Date:  2022-03-11       Impact factor: 4.009

Review 7.  In Silico Modeling and Simulation to Guide Bioequivalence Testing for Oral Drugs in a Virtual Population.

Authors:  Fan Zhang; Ranran Jia; Huitao Gao; Xiaofei Wu; Bo Liu; Hongyun Wang
Journal:  Clin Pharmacokinet       Date:  2021-06-30       Impact factor: 5.577

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.